Who owns JNJWhat JNJ owns
What Johnson & Johnson owns
The company's own 13F portfolio · as of 2026-03-31 · long US-listed stakes only — private holdings, bonds and cash are not disclosable on a 13F
$652.4M
disclosed stock portfolio
16
positions
39.6%
in PTGX
Positions, as of 2026-03-31
ordered by filed value · % of book = share of the disclosed stock portfolio · PUT/CALL tags = options positions (share-equivalents), not shares held
| # | Issuer | Shares | Value | % of book |
|---|---|---|---|---|
| 1 | PTGXProtagonist Therapeutics Inc. | 2.4M | $258.1M | 39.6% |
| 2 | Nanobiotix S.A. | 5.6M | $173.6M | 26.6% |
| 3 | MeiraGTx Holdings plc | 6.6M | $57.5M | 8.8% |
| 4 | RAPPRapport Therapeutics, Inc. | 1.8M | $55.8M | 8.6% |
| 5 | CVRx, Inc. | 4.0M | $38.1M | 5.8% |
| 6 | Contineum Therapeutics Inc. | 2.0M | $25.8M | 4% |
| 7 | LEGNLegend Biotech Corporation | 814,586 | $14.7M | 2.3% |
| 8 | XNCRXencor, Inc. | 748,062 | $9.0M | 1.4% |
| 9 | PRCTProcept BioRobotics Corporation | 357,939 | $9.0M | 1.4% |
| 10 | Fate Therapeutics, Inc. | 3.4M | $4.1M | 0.6% |
| 11 | Neumora Therapeutics, Inc. | 1.8M | $3.6M | 0.6% |
| 12 | Rallybio Corporation | 152,901 | $1.4M | 0.2% |
| 13 | Vor Biopharma, Inc. | 53,732 | $958,579 | 0.1% |
| 14 | Standard BioTools, Inc. | 311,967 | $286,791 | 0% |
| 15 | Nano-X Imaging Ltd. | 83,554 | $189,668 | 0% |
| 16 | Adicet Bio, Inc. | 22,779 | $155,125 | 0% |
Source: SEC Form 13F-HR filed by JOHNSON & JOHNSON (CIK 200406), reporting period 2026-03-31. Values are quarter-end filed marks. Research, not investment advice.